Education
About Us
Working with TipRanks
Follow Us
NovoCure Ltd (NVCR)
NASDAQ:NVCR
Top Page
NovoCure
(NASDAQ:NVCR)
Select Model
Select Model
Rating:48Neutral
Price Target:
$14.00
▲(2.41% Upside)
Action:ReiteratedDate:12/09/25
NovoCure's overall stock score is primarily impacted by its financial challenges, including negative profitability and high leverage. While there are positive developments, such as international expansion and regulatory approvals, these are offset by operational inefficiencies and valuation concerns. The technical indicators suggest a lack of strong momentum, further contributing to the moderate score.
Positive Factors
International Expansion
International expansion into key markets like France, Japan, and Germany enhances NovoCure's global footprint, diversifying revenue streams and reducing reliance on any single market, which is crucial for long-term growth and stability.
Regulatory Progress
Regulatory approval in Japan for Optune Lua in NSCLC treatment strengthens NovoCure's market position, potentially increasing adoption and revenue through new therapeutic options in a significant market.
Leadership Change
The appointment of Frank Leonard as CEO, with his extensive experience at NovoCure, is expected to provide strategic continuity and leadership stability, guiding the company through future transformative milestones.
Negative Factors
High Leverage
High leverage poses financial risk, limiting NovoCure's flexibility to invest in growth opportunities and potentially impacting its ability to weather economic downturns or operational challenges.
Negative Profitability
Negative profitability margins indicate ongoing operational challenges, which may hinder NovoCure's ability to reinvest in its business, affecting long-term growth and shareholder value.
Cash Flow Concerns
Negative cash flow highlights difficulties in generating sufficient cash from operations, which could strain NovoCure's ability to fund its growth initiatives and meet financial obligations.
NovoCure (NVCR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.56B
Dividend YieldN/A
Average Volume (3M)2.26M
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue Growth11.17%
EPS Growth-15.64%
CountryUS
Employees1,488
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.22
Shares Outstanding111,981,980
10 Day Avg. Volume3,903,974
30 Day Avg. Volume2,263,561
Financial Highlights & Ratios
PEG Ratio0.95
Price to Book (P/B)8.92
Price to Sales (P/S)5.31
P/FCF Ratio-46.42
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue2.54
Enterprise Value/Gross Profit3.37
Enterprise Value/Ebitda-15.18
Forecast
1Y Price Target
$25.50Price Target Upside86.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.6
Revenue Forecast (FY)$681.49M
NovoCure Business Overview & Revenue Model
Company DescriptionNovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
How the Company Makes MoneyNovoCure generates revenue primarily through the sale of its Optune devices and related consumables, such as the TTFields transducer arrays, which are used in conjunction with the therapy. The company also earns revenue from insurance reimbursements, as many health insurance plans cover the cost of Optune therapy for eligible patients. Significant partnerships with healthcare providers and collaborations with research institutions enhance its market reach and credibility. Additionally, NovoCure may benefit from expanding its indications for TTFields therapy beyond glioblastoma and mesothelioma, creating new revenue opportunities.
NovoCure Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 23, 2026
Earnings Call Sentiment Positive
The call presented a mix of strong commercial and clinical progress (record revenue, meaningful active patient growth, FDA approval of Optune Pax, upcoming trial readouts, improved non‑GBM revenue trajectory, solid cash position and convertible note repayment) alongside near‑term profitability and operational challenges (net losses and negative adjusted EBITDA, gross margin compression, increased R&D spend, slower Optune Lua launch, reimbursement timing for Optune Pax, and a resolved Medicare administrative issue). Management provided formal 2026 guidance (revenue growth of 3%–8% and adjusted EBITDA of negative $20 million to breakeven), signifying a clear path toward stabilizing growth and driving to profitability while acknowledging near‑term execution and reimbursement risks.Q4-2025 Updates
Positive Updates
Record Revenue and Year‑Over‑Year Growth
Full‑year net revenue of $655 million and fourth quarter net revenue of $174 million, each representing 8% year‑over‑year growth versus 2024.
Strong Active Patient Growth in Key International Markets
Notable active patient growth ex‑U.S.: Germany +10% YoY, France +19% YoY, Japan +29% YoY; U.S. active patients grew +4% YoY.
FDA Approval of Optune Pax with Rapid Review
Optune Pax approved Feb 11 for locally advanced pancreatic cancer (first‑line with nab‑paclitaxel + gemcitabine); FDA review completed at the 180‑day mark (faster than typical 9–12 month PMA timeline). U.S. launch has commenced and filings submitted in EU and Japan.
Pipeline and Clinical Catalysts Upcoming
Presented final data from two large randomized trials and published in major journals; PMA submissions for pancreatic cancer and brain metastases in place. Top‑line readouts expected: PANOVA‑4 next month, TRIDENT in Q2, and KEYNOTE‑58 Phase III enrollment expected complete by year‑end.
Growing Non‑GBM Revenue Trajectory
Optune Lua revenue totaled $10.4 million for 2025 (including $5.8 million from NSCLC); Q4 Optune Lua recognition $3.5 million (including $2.4 million for NSCLC). Company expects non‑GBM contributions of $15 million–$25 million in 2026 vs $10 million in 2025.
Solid Liquidity and Debt Reduction
Cash and investments of $448 million at year‑end and repayment of $561 million of convertible notes in Q4. Only $200 million drawn on the credit facility and management does not plan additional draws, providing runway while new revenue streams ramp.
First Formal Guidance and Path to Profitability
Issued 2026 revenue guidance of $675 million–$705 million (3%–8% YoY growth at constant FX) and adjusted EBITDA guidance of negative $20 million to breakeven, signaling a clear objective to reach adjusted EBITDA breakeven in 2026.
Cost Discipline and Operating Efficiency Signals
Full‑year sales & marketing expense flat at $240 million YoY and Q4 G&A down 41% (Q4 $43 million) with full‑year G&A down 6% to $178 million, driven by lower share‑based compensation in the period.
Negative Updates
Continued Net Losses and Negative Adjusted EBITDA
Net loss for Q4 was $24 million (loss per share $0.22) and full‑year net loss was $136 million (loss per share $1.22). Adjusted EBITDA was negative $16 million in Q4 and negative $34 million for the full year.
Gross Margin Compression
Gross margin declined to 76% in Q4 and 75% for the full year versus 79% and 77% in 2024, driven by decreased prior‑period collections in the U.S. and increased costs (tariffs/other rate impacts). Management expects gross margin in the mid‑70s in 2026.
Rising R&D Spend
Research & development expense increased 19% in Q4 to $61 million and rose 7% for the full year to $225 million, driven by costs for the KEYNOTE‑58 and LUNAR‑2 Phase III trials and regulatory activity.
Optune Lua Launch Underperformance
Optune Lua launch has been slower than projected in the U.S. and Germany; full‑year Optune Lua revenue totaled $10.4 million. Management has rightsized marketing spend and reprioritized investments toward higher‑return indications.
Reimbursement and Coverage Lag for New Indications
Optune Pax revenue may lag active patient starts due to the need to secure payer coverage and contracts; management expects 1–2 years to achieve routine commercial payer coverage and highlights importance of NCCN inclusion to accelerate reimbursement.
Temporary Medicare Billing Privileges Issue
CMS halted Medicare billing privileges during a DME supplier revalidation process; the company submitted a corrective action plan and completed reinspection; CMS rescinded revocation and reinstated privileges retroactive to Dec 17, 2025. Issue resolved but reflected administrative/regulatory risk.
Upcoming Share‑Based Compensation Charge
Q1 will include a similar G&A share‑based compensation charge triggered by the Optune Pax approval, indicating near‑term non‑cash expense pressure.
Modest Near‑Term Revenue from New Market Launches
Planned launches in Spain, Czechia, and British Columbia (Optune Gio) and Optune Lua launch in Japan are expected to provide modest contributions in 2026 as these markets ramp.
Company Guidance
NovoCure issued 2026 guidance of $675–$705 million in net revenue at constant FX (up 3%–8% year‑over‑year), assuming Optune Gio growth in the low‑ to mid‑single‑digit range and $15–$25 million of revenue from non‑GBM products (vs. $10 million in 2025), and targeting adjusted EBITDA of negative $20 million to breakeven for the year; they expect gross margin in the mid‑70s percent range and noted a 1–2 year timeline to routine commercial payer coverage for new indications. For context, full‑year 2025 net revenue was $655 million (Q4 $174 million), with FY gross margin 75% (Q4 76%; prior year FY/Q4: 77%/79%), adjusted EBITDA of negative $34 million for FY2025 (Q4 negative $16 million), cash & investments of $448 million, repayment of $561 million of convertible notes in Q4, and no plan to draw beyond the $200 million already accessed on the credit facility. Additional 2025 metrics that inform guidance include Optune Lua revenue of $10.4 million for the year ($3.5 million in Q4, $2.4 million from NSCLC), an FX tailwind of ~$11 million for FY2025 (~$5 million in Q4), R&D spend of $225 million for the year ($61 million Q4), sales & marketing $240 million FY ($69 million Q4), G&A $178 million FY ($43 million Q4), and net loss of $136 million for FY2025 (EPS −$1.22; Q4 net loss $24 million, EPS −$0.22).NovoCure Financial Statement Overview
Summary
NovoCure faces significant financial challenges, with negative profitability and high leverage. While revenue is growing slowly, the company must address its operational inefficiencies and improve cash flow to stabilize its financial position. The strong gross profit margin is a positive indicator, but the overall financial health requires careful management to mitigate risks associated with high debt levels and negative cash flows.Income Statement
NovoCure's revenue has shown modest growth with a TTM increase of 1.92%. However, the company is experiencing negative profitability margins, with a TTM net profit margin of -27.66% and an EBIT margin of -18.84%. The gross profit margin remains strong at 75.37%, indicating efficient cost management, but the negative EBIT and net profit margins highlight ongoing operational challenges.45
Neutral
Balance Sheet
The balance sheet shows a high debt-to-equity ratio of 2.34 in the TTM period, indicating significant leverage. Return on equity is negative at -50.29%, reflecting ongoing losses. The equity ratio is not provided, but the high leverage suggests potential financial risk if revenue growth does not improve.40
Negative
Cash Flow
Cash flow analysis reveals negative operating cash flow and free cash flow in the TTM period, with a free cash flow growth rate of -18.94%. The free cash flow to net income ratio is positive at 1.89, suggesting that cash flow is better than net income, but overall cash generation remains a concern.35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 642.27M | 605.22M | 509.34M | 537.84M | 535.03M | 494.37M |
| Gross Profit | 484.08M | 468.04M | 381.06M | 422.97M | 420.15M | 387.87M |
| EBITDA | -107.50M | -109.58M | -177.45M | -67.89M | -38.38M | 44.83M |
| Net Income | -177.65M | -168.63M | -207.04M | -92.53M | -58.35M | 19.81M |
Balance Sheet | ||||||
| Total Assets | 1.36B | 1.24B | 1.15B | 1.19B | 1.14B | 1.05B |
| Cash, Cash Equivalents and Short-Term Investments | 1.04B | 959.87M | 910.62M | 969.42M | 938.51M | 854.08M |
| Total Debt | 797.94M | 683.35M | 596.24M | 584.27M | 581.90M | 450.68M |
| Total Liabilities | 1.02B | 880.61M | 783.63M | 750.48M | 729.00M | 575.46M |
| Stockholders Equity | 341.33M | 360.18M | 362.50M | 441.17M | 410.49M | 476.53M |
Cash Flow | ||||||
| Free Cash Flow | -65.17M | -69.22M | -100.43M | 9.43M | 58.59M | 84.18M |
| Operating Cash Flow | -34.48M | -26.37M | -73.34M | 30.79M | 82.76M | 99.15M |
| Investing Cash Flow | 78.74M | -140.24M | 184.15M | -139.96M | -144.83M | -472.85M |
| Financing Cash Flow | 110.84M | 90.31M | 15.79M | 15.49M | 25.70M | 440.21M |
NovoCure Technical Analysis
Positive
13.67
Price Trends
12.72
Positive
12.71
Positive
13.76
Negative
Market Momentum
0.17
Negative
58.34
Neutral
72.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVCR, the sentiment is Positive. The current price of 13.67 is above the 20-day moving average (MA) of 11.66, above the 50-day MA of 12.72, and below the 200-day MA of 13.76, indicating a neutral trend. The MACD of 0.17 indicates Negative momentum. The RSI at 58.34 is Neutral, neither overbought nor oversold. The STOCH value of 72.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NVCR.
NovoCure Risk Analysis
NovoCure disclosed 41 risk factors in its most recent earnings report. NovoCure reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NovoCure Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | C$77.16B | 24.61 | 14.30% | 2.45% | -6.18% | -14.06% | |
63 Neutral | $1.17B | -352.26 | -5.20% | ― | -18.82% | 92.56% | |
60 Neutral | $1.56B | -129.71 | -2.40% | ― | 15.80% | 26.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.56B | -11.18 | -50.60% | ― | 11.17% | -15.64% | |
45 Neutral | $1.55B | -1.36 | -46.15% | ― | -3.43% | 38.98% | |
42 Neutral | $182.64M | -4.71 | -27.19% | ― | 30.55% | -340.19% |
* Healthcare Sector Average
NVCR
NovoCure
13.67
-4.74
-25.75%
ATRC
Atricure
31.26
-7.70
-19.76%
TSE:IMO
Imperial Oil
159.55
65.90
70.37%
QDEL
QuidelOrtho
22.74
-16.31
-41.77%
BLFS
BioLife Solutions
24.20
-0.31
-1.26%
SMTI
Sanara MedTech
20.44
-12.38
-37.72%
NovoCure Corporate Events
Business Operations and StrategyExecutive/Board Changes
NovoCure Appoints Frank Leonard as New CEO
Neutral
Dec 1, 2025
On November 24, 2025, Ashley Cordova resigned as CEO and Director of Novocure, effective November 30, 2025, with no disagreements reported. Frank Leonard, previously the company’s President, was appointed as the new CEO effective December 1, 2025. Leonard, who has been with Novocure since 2010, has played a significant role in the company’s operations and strategy, and his appointment is expected to guide the company through future transformative milestones.
The most recent analyst rating on (NVCR) stock is a Sell with a $11.50 price target. To see the full list of analyst forecasts on NovoCure stock, see the NVCR Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.